title: Membrane damage-induced vesicle-vesicle fusion of dysferlin-containing vesicles in muscle cells requires microtubules and kinesin.
abstract: Mutations in the dysferlin gene resulting in dysferlin-deficiency lead to limb-girdle muscular dystrophy 2B and Myoshi myopathy in humans. Dysferlin has been proposed as a critical regulator of vesicle-mediated membrane resealing in muscle fibers, and localizes to muscle fiber wounds following sarcolemma damage. Studies in fibroblasts and urchin eggs suggest that trafficking and fusion of intracellular vesicles with the plasma membrane during resealing requires the intracellular cytoskeleton. However, the contribution of dysferlin-containing vesicles to resealing in muscle and the role of the cytoskeleton in regulating dysferlin-containing vesicle biology is unclear. Here, we use live-cell imaging to examine the behavior of dysferlin-containing vesicles following cellular wounding in muscle cells and examine the role of microtubules and kinesin in dysferlin-containing vesicle behavior following wounding. Our data indicate that dysferlin-containing vesicles move along microtubules via the kinesin motor KIF5B in muscle cells. Membrane wounding induces dysferlin-containing vesicle-vesicle fusion and the formation of extremely large cytoplasmic vesicles, and this response depends on both microtubules and functional KIF5B. In non-muscle cell types, lysosomes are critical mediators of membrane resealing, and our data indicate that dysferlin-containing vesicles are capable of fusing with lysosomes following wounding which may contribute to formation of large wound sealing vesicles in muscle cells. Overall, our data provide mechanistic evidence that microtubule-based transport of dysferlin-containing vesicles may be critical for resealing, and highlight a critical role for dysferlin-containing vesicle-vesicle and vesicle-organelle fusion in response to wounding in muscle cells.
authors.affiliation: Department of Molecular & Integrative Physiology, University of Michigan Ann Arbor, MI 48109, USA.
authors.forename: Joel R
authors.initials: JR
authors.lastname: McDade
authors.forename: Daniel E
authors.initials: DE
authors.lastname: Michele
mesh_terms: D000818:Animals; D002460:Cell Line; D002462:Cell Membrane / Q000473:pathology*; D022162:Cytoplasmic Vesicles / Q000473:pathology*; D049452:Green Fluorescent Proteins; D006576:Heterocyclic Compounds, 4 or More Rings / Q000494:pharmacology; D016547:Kinesins / Q000235:genetics / Q000378:metabolism*; D008247:Lysosomes / Q000378:metabolism; D008561:Membrane Fusion / Q000502:physiology*; D008565:Membrane Proteins / Q000235:genetics*; D008870:Microtubules / Q000378:metabolism*; D032342:Muscle Cells / Q000166:cytology; D018485:Muscle Fibers, Skeletal / Q000378:metabolism; D009124:Muscle Proteins / Q000235:genetics*; D018482:Muscle, Skeletal / Q000378:metabolism; D049288:Muscular Dystrophies, Limb-Girdle / Q000235:genetics; D024462:Myosin Type II / Q000037:antagonists & inhibitors; D015739:Nocodazole / Q000494:pharmacology; D051381:Rats; D050257:Tubulin Modulators / Q000494:pharmacology
chemical_list: C547052:Dysf protein, rat; D006576:Heterocyclic Compounds, 4 or More Rings; C521566:KIF5B protein, rat; D008565:Membrane Proteins; D009124:Muscle Proteins; D050257:Tubulin Modulators; D049452:Green Fluorescent Proteins; C472645:blebbistatin; D024462:Myosin Type II; D016547:Kinesins; D015739:Nocodazole